iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

BRYAN, Texas, May 04, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it has successfully resolved its lawsuit with Fraunhofer USA, Inc. (“Fraunhofer USA”). The parties' settlement confirms iBio's ownership of certain intellectual property related to plant-based biopharmaceutical production. As part of the settlement, iBio granted Fraunhofer USA a fully paid-up license to use the recombinant protein manufacturing technologies that were the subject of litigation.

iBio and Fraunhofer USA Conclude Litigation and Enter License Agreement

Moderna

Novavax

Ocugen, Inc.

VanEck Vectors Pharmaceutical ETF

Sorrento Therapeutics Inc

AstraZeneca

Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now. The post 7 Pharmaceutical Stocks That Could Get a Covid Hangover appeared first on InvestorPlace.

7 Pharmaceutical Stocks That Could Get a Covid Hangover

Alpha Pro Tech

DocuSign

Peloton

Because of the pandemic, many so-called Covid stocks enjoyed outsized gains but investors might want to consider trimming their exposure. The post Take Your Profits!

Take Your Profits! 7 Covid Winners to Sell Now

Don't bet on iBio for its coronavirus vaccine candidate. It's the company's FastPharming System that could move IBIO stock in the long term.

The Top Reason to Consider iBio Stock in the Long Term

IBIO stock is not likely to move higher given its huge dilution. I think it is not worth more than 48 cents per share.

iBio Stock Is Not Likely To Move Higher Given Its Huge Dilution

AIM ImmunoTech Inc

Asensus Surgical

Celsion

Jaguar Health

Ovid Therapeutics

Rigel Pharmaceuticals

VBI Vaccines

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

8 Biotech Penny Stocks for Investors to Watch

BRYAN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it will participate in the 33rd Annual Roth Conference, which will be held virtually from March 15-17, 2021.

iBio to Participate in the 33rd Annual Roth Conference

Borr Drilling Ltd

Evofem Biosciences Inc

Safe Bulkers

Timber Pharmaceuticals

These penny stocks are companies that have a crucial year ahead in terms of industry turnaround or company specific product development. The post 7 Penny Stocks In a Make-or-Break Year appeared first on InvestorPlace.

7 Penny Stocks In a Make-or-Break Year

With iBio making key executive-level appointments and recording excellent fiscal stats, IBIO stock's value proposition is hard to ignore. The post Hold iBio Shares as Q2 Highlights Strong Product Catalog appeared first on InvestorPlace.

Hold iBio Shares as Q2 Highlights Strong Product Catalog

Bausch Health Companies Inc

DiaMedica Therapeutics Inc

Oncolytics Biotech, Inc.

Outlook Therapeutics Inc

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates.

Why Bausch Health, Oncolytics Biotech, And More Are Moving Today

iBio, Inc. (IBIO) CEO Tom Isett on Q2 2021 Results - Earnings Call Transcript

BRYAN, Tx., Feb. 16, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended December 31, 2020.

iBio Reports Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update

Castor Maritime Inc

Genius Brands

Northern Dynasty Minerals

Cenntro Electric Group

SNDL Inc.

Uxin Ltd - ADR

In the midst of an expensive market, traders are turning to penny stocks as a cheaper alternative. But avoid these seven risky penny names.

7 Penny Stocks That Look Far Too Risky to Bet On

BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 second quarter financial results after market close on Tuesday, February 16, 2021. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021

Ibio (IBIO) stock is on the rise Thursday despite a lack of news coming out today that would result in the movement today. The post IBIO Stock: 5 Things for Investors to Know About iBio Today as Shares Zoom Higher appeared first on InvestorPlace.

IBIO Stock: 5 Things for Investors to Know About iBio Today as Shares Zoom Higher

Ceragon Networks

FinVolution Group

Himax Tech

Kopin

Ribbon Communications

StoneMor Partners

We may be seeing some sector rotation, and many companies that have made big moves in recent weeks have stocks under $10. The post 7 Stocks Under $10 to Buy for February  appeared first on InvestorPlace.

7 Stocks Under $10 to Buy for February

The stock price of IBIO Inc (NYSEAMERICAN: IBIO) increased by 20.55%. This is why it happened.

IBIO Stock Price Increased 20.55%: Why It Happened

Shares of IBIO stock are taking off on Friday after an analyst from Cantor Fitzgerald initiated an Overweight rating and $3 price target. The post IBIO Stock Alert: Analyst Call Sends Shares of Pharma iBio Soaring appeared first on InvestorPlace.

IBIO Stock Alert: Analyst Call Sends Shares of Pharma iBio Soaring

AquaBounty Technologies

CTI BioPharma

Alpine Immune Sciences

These 4 Micro-Cap Healthcare Stocks Gained the Most in 2020

Big 5 Sporting Goods

Beyond Meat

Camping World Hlds

Ford Motor Company

GameStop

Nikola

Obviously, we'll never forget this tumultuous year. During a calendar full of pandemic panic, economic crisis and social unrest, here are my best calls (and worst calls) of 2020.

10 Best and Worst Calls of 2020

BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January 18, 2020.

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

Harley-Davidson

Intel

Wells Fargo

Hertz

Luckin Coffee

Electrameccanica

It's the time to clean house and make portfolio space for stronger investment opportunities during 2021. Here are 7 stocks to sell.

7 Stocks To Sell For A Fresh Start On New Year's Day

Hall of Fame Resort & Entertainment

Simon Property Group

Washington Prime Group

Alkaline Water Company Inc (The)

Chesapeake Energy

Value stocks are surging lately. That's caused many penny stocks to roar back to life.

7 Penny Stocks With Further to Fall

BRYAN, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the closing of its underwritten public offering of approximately 29.7 million shares of its common stock for gross proceeds of $35.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by iBio. In addition, iBio has granted the underwriter a 30-day option to purchase up to approximately 4.4 million additional shares of its common stock.

iBio Announces Closing of its Public Offering of Common Stock

IBIO stock remains volatile as the company continues its focus on a breakthrough product to combat the coronavirus pandemic. The post Be Wary as iBio Seeks a Place in the Vaccine Game appeared first on InvestorPlace.

Be Wary as iBio Seeks a Place in the Vaccine Game

News for iBio Stock (IBIO)